Skip to main content
. 2016 Mar 11;11(3):e0150955. doi: 10.1371/journal.pone.0150955

Fig 3. Plasma-concentration time profiles of MDMA and metabolites.

Fig 3

Plasma-concentration time profiles for R- and S-MDMA and R- and S-MDA, R- and S-DHMA 3-sulfate and R- and S-DHMA 4-sulfate, and R- and S-HMMA sulfate and R- and S-HMMA glucuronide. Black circles and solid lines represent 13 CYP2D6 extensive metabolizers (EM) after placebo-MDMA administration. Triangles and dotted lines represent three CYP2D6 intermediate metabolizers (IM) after placebo+MDMA administration. Open circles and solid lines represent 13 CYP2D6 EMs after bupropion+MDMA administration. The data are expressed as mean and SEM. *p < 0.05, **p < 0.01, ***p < 0.001, significant within-subject difference between placebo+MDMA and bupropion+MDMA in CYP2D6 EM subjects (Wilcoxon matched-pairs test); +p < 0.05, ++p < 0.01, significant difference between placebo+MDMA-treated CYP2D6 IMs and bupropion+MDMA-treated CYP2D6 EMs (Mann-Whitney test).